CARLSBAD, Calif.--(BUSINESS WIRE)--Applied Biosystems, a division of Life Technologies Corporation (NASDAQ:LIFE), today announced the introduction of a new line of genotyping assays that enable researchers to more closely study the significant role that DNA copy number structural variation plays in human health and disease. The TaqMan® Copy Number Assays are designed to detect and quantify copy number variations (CNVs), which are one of the most frequently occurring forms of structural change within a genome. These assays will enable pharmaceutical, clinical and academic researchers to accurately detect CNVs, which are changes in the number of copies of a gene, a part of a gene, or a large stretch of DNA that occur throughout a genome.
